FDA Issues Early Alert for Impella Heart Pump Sensor Malfunction Linked to 22 Patient Injuries
核心洞察
The FDA issued an early alert warning about differential pressure sensor malfunctions in Impella RP with SmartAssist (搜索) and Impella RP Flex with SmartAssist (搜索) heart pump devices.
The sensor malfunction causes inaccurate pump flow readings and placement signals on the automated controller, leading to incorrect clinical interventions.
As of January 15, Abiomed reported 22 serious injuries associated with the issue, though the devices' hemodynamic support capabilities remain unaffected.
The US Food and Drug Administration has issued an early alert warning healthcare providers about a potentially serious malfunction affecting Impella RP with SmartAssist (搜索) and Impella RP Flex with SmartAssist (搜索) heart pump devices manufactured by Abiomed, a Johnson & Johnson MedTech (搜索) company. The alert follows reports of 22 patient injuries linked to differential pressure sensor failures in these temporary cardiac support devices.
Sensor Malfunction Details
According to the FDA, the differential pressure sensor in affected devices can malfunction, causing sensor values to drift over time. This technical failure results in inaccurate readings displayed on the automated Impella controller, including pump flow measurements, pulmonary artery placement signals, pulmonary artery pulsatility index, and central venous placement signals.
While the sensor malfunction does not compromise the devices' core hemodynamic support capabilities, the inaccurate controller readings have led to problematic clinical interventions. Healthcare providers have made incorrect P-level flow adjustments and performed unnecessary pump exchanges based on the faulty sensor data.
Company Response and Safety Measures
In response to the identified safety issue, Abiomed issued an urgent medical device correction on January 27, providing updated use instructions for clinicians. The company has recommended that healthcare providers rely on P-level flow rates listed in the official instructions for use rather than trusting the controller display values.
Additional safety recommendations include verifying device positioning through imaging techniques and monitoring patient hemodynamics using approved diagnostic devices independent of the Impella controller readings.
Clinical Impact and Device Function
The Impella RP with SmartAssist (搜索) and Impella RP Flex with SmartAssist (搜索) are temporary heart pumps specifically designed to provide right heart support in patients experiencing acute right heart failure (搜索). Despite the sensor malfunction, the FDA emphasized that the devices retain their ability to deliver essential hemodynamic support to critically ill patients.
As of January 15, Abiomed reported 22 serious injuries associated with the sensor malfunction issue, with no deaths reported in connection with this specific problem. The FDA's early alert system allows for rapid communication of emerging safety concerns while formal regulatory processes continue.